EGFR and colorectal carcinoma: Recently, immunotherapy targeting epidermal growth factor receptor (EGFR) and immune checkpoints has aroused wide concern about CRC therapy.4-6 A clinical trial demonstrated that approximately 50% of metastatic CRC patients who received EGFR monoclonal antibodies and chemotherapy survived 2-4 months longer than those who received chemotherapy alone.